A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2013
At a glance
- Drugs Pexidartinib (Primary)
- Indications Hodgkin's disease
- Focus Biomarker; Therapeutic Use
- 19 Jan 2013 New source identified and integrated (M.D. Anderson Cancer Center record: 2010-0649).
- 08 May 2012 Planned End Date changed from 1 Feb 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
- 21 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.